Gene Therapy Process Development Summit

Optimizing and Platforming Upstream Gene Therapy Process Development to Develop Scalable, Repeatable and Cost-Effective Manufacturing Processes to Deliver Rare Disease Drugs

Time: 8:00 AM – 4:00 PM

Venue Details: Le Meridien Philadelphia, 1421 Arch Street, Philadelphia, Pennsylvania, 19102, United States

Prices:
Drug Developer Pricing – 2-Day Conference: USD 2999.00,
Solution Provider Pricing – 2-Day Conference: USD 3799.00

Speakers: Brad Mickey, Executive Director, Manufacturing and Operations Site Head, Astellas Gene Therapies, David McNally, Head of Viral Vector Technology, University of Massachusetts Chan Medical School, Gary Todd, VP – Head of Technologies, Lacerta Therapeutics, Huiren Zhao, Principal Scientist, Amgen Inc., Jun Li, Associate Director – Upstream Process Development and Gene Therapy, Ultragenyx, Margaret Liu, Professor at the William G. Lowrie Department of Chemical and Biomolecular Engineering, James Comprehensive Cancer Centre, Oluwatoyin Areo, Research Advisor, Bioassay Development, Ping Liu, Associate Director and Head of Cell Line Development, REGENXBIO, Po-Yi Ho, Senior Scientist, Analytical Development, Carbon Biosciences, Pranav Joshi, Associate Director – Upstream Process Development, Gene Therapy Program at The University of Pennsylvania, Scott Burger, Principal Consultant, Advanced Cell and Gene Therapy, Seema Bhatlekar, Gene Therapy and Process Development Scientist, Janssen, Steve Greenway, Associate Director – Upstream Process Development, Vesigen Therapeutics, Vincent Wiegmann, Upstream Process Development Senior Scientist I, MeiraGTx, Yi Pu, Group Head, Prime Medicine